Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas

Table 2 Univariable analysis of prognostic parameters for survival in Ren Ji cohort patients with gastric neuroendocrine carcinomas

Prognostic parameter	Univariable analysis
	HR	95%CI	P value
Age (yr)
< 60	1.0 (reference)
≥ 60	2.718	0.921-8.023	0.070
Gender
Male	1.0 (reference)
Female	0.915	0.308-2.718	0.873
Tumor location
Cardiac	1.0 (reference)
Corpus	3.034	1.100-8.374	0.032
Antrum	2.331	0.817-6.648	0.114
Residual stomach anastomosis	1.401	0.176-11.159	0.750
Tumor size
≤ 5 cm	1.0 (reference)
> 5 cm	1.605	0.693-3.717	0.269
T classification
T1 + T2	1.0 (reference)
T3 + T4	0.760	0.407-1.420	0.390
Lymph node metastasis
≤ 7	1.0 (reference)
> 7	2.766	1.101-6.948	0.030
Liver metastasis
Absent	1.0 (reference)
Present	3.515	1.269-9.731	0.016
Adjuvant chemotherapy
No-chemotherapy	1.0 (reference)
Present	0.226	0.076-0.674	0.008
Chemotherapy regimen
No-chemotherapy	1.0 (reference)
EP	0.138	0.029-0.667	0.014
EP + PTX	0.059	0.012-0.298	0.001
Other chemotherapy	0.426	0.140-1.296	0.133

The bold number represents the P values with significant differences. EP: Etoposide plus cisplatin; EP + PTX: EP plus Paclitaxel.